Trial Profile
A comparison of the efficacy of Symbicort [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre 26-weeks study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Antiasthmatics
- Indications Asthma
- Focus Therapeutic Use
- 21 Jan 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
- 07 Oct 2008 Results were reported at the Annual Congress of the European Respiratory Society.
- 07 Oct 2008 Primary endpoint 'Time to exacerbation of symptoms' has been met.